219 Ta AD, Ollberding NJ, Karns R, Haberman Y, Alazraki AL, Hercules D, et al. Association of Baseline Luminal NarrowingWith Ileal Microbial Shifts and Gene Expression Programs and Subsequent Transmural Healing in Pediatric Crohn Disease. Inflamm Bowel Dis 2021;27(11):1707-1718. doi: 10.1093/ibd/izaa339. Liu S, Zhao W, Lan P, Mou X. The microbiome in inflammatory bowel diseases: from pathogenesis to therapy. Protein Cell 2021;12(5):331-345. doi: 10.1007/s13238-020-00745-3. Hall AB, Yassour M, Sauk J, Garner A, Jiang X, Arthur T, et al. A novel Ruminococcus gnavus clade enriched in inflammatory bowel disease patients. Genome Med 2017;9(1):103. doi: 10.1186/s13073-017-0490-5. Long C, Venema K. Pretreatment of RapeseedMeal Increases Its Recalcitrant Fiber Fermentation andAlters the Microbial Community in an in vitro Model of Swine Large Intestine. Front Microbiol 2020;11:588264. doi: 10.3389/fmicb.2020.588264. Baxter NT, Schmidt AW, Venkataraman A, Kim KS, Waldron C, Schmidt TM. Dynamics of Human Gut Microbiota and Short-Chain Fatty Acids in Response to Dietary Interventions with Three Fermentable Fibers. mBio 2019;10(1):e02566-18. doi: 10.1128/mBio.02566-18. Morrison DJ, Preston T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes 2016;7(3):189-200. doi: 10.1080/19490976.2015.1134082. Wang Y, Gao X, Ghozlane A, Hu H, Li X, Xiao Y, et al. Characteristics of Faecal Microbiota in Paediatric Crohn’s Disease and Their Dynamic Changes During Infliximab Therapy. J Crohns Colitis 2018;12(3):337346. doi: 10.1093/ecco-jcc/jjx153. Ventin-Holmberg R, Eberl A, Saqib S, Korpela K, Virtanen S, Sipponen T, et al. Bacterial and Fungal Profiles as Markers of Infliximab Drug Response in Inflammatory Bowel Disease. J Crohns Colitis 2021;15(6):10191031. doi: 10.1093/ecco-jcc/jjaa252. Dovrolis N, Michalopoulos G, Theodoropoulos GE, Arvanitidis K, Kolios G, Sechi LA, et al. The Interplay betweenMucosal Microbiota Composition and Host Gene-Expression is Linkedwith Infliximab Response in Inflammatory Bowel Diseases. Microorganisms 2020;8(3):438. doi: 10.3390/microorganisms8030438. Aden K, Rehman A, Waschina S, Pan WH, Walker A, Lucio M, et al. Metabolic Functions of Gut Microbes Associate With Efficacy of Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases. Gastroenterology 2019;157(5):1279-1292.e11. doi: 10.1053/j.gastro.2019.07.025. Schierova D, Roubalova R, Kolar M, Stehlikova Z, Rob F, Jackova Z, et al. Fecal Microbiome Changes and Specific Anti-Bacterial Response in Patients with IBD during Anti-TNF Therapy. Cells 2021;10(11):3188. doi: 10.3390/cells10113188. Nepelska M, deWouters T, Jacouton E, Béguet-Crespel F, Lapaque N, Doré J, et al. Commensal gut bacteria modulate phosphorylation-dependent PPARγ transcriptional activity in human intestinal epithelial cells. Sci Rep 2017;7:43199. doi: 10.1038/srep43199. Byndloss MX, Olsan EE, Rivera-Chávez F, Tiffany CR, Cevallos SA, Lokken KL, et al. Microbiota-activated PPAR-γ signaling inhibits dysbiotic Enterobacteriaceae expansion. Science 2017;357(6351):570-575. doi: 10.1126/science.aam9949. Abbot EL, McCormack JG, Reynet C, Hassall DG, Buchan KW, Yeaman SJ. Diverging regulation of pyruvate dehydrogenase kinase isoform gene expression in cultured human muscle cells. FEBS J 2005;272(12):3004-14. doi: 10.1111/j.1742-4658.2005.04713.x. Bowman TA, O’Keeffe KR, D’Aquila T, Yan QW, Griffin JD, Killion EA, et al. Acyl CoA synthetase 5 (ACSL5) ablation in mice increases energy expenditure and insulin sensitivity and delays fat absorption. Mol Metab 2016;5(3):210-220. doi: 10.1016/j.molmet.2016.01.001. Kumar J, Rani K, Datt C. Molecular link between dietary fibre, gut microbiota and health. Mol Biol Rep 2020;47(8):6229-6237. doi: 10.1007/s11033-020-05611-3. Mucosal host-microbe interactions in IBD 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82
RkJQdWJsaXNoZXIy MjY0ODMw